ABBVIE

AbbVie's phase 2 EMPOWER trials of emraclidine for schizophrenia did not meet primary endpoint of PANSS improvement. Emraclidine was well-tolerated with a safety profile similar to phase 1b trial. AbbVie remains committed to psychiatric and neurological disorder treatments.

Bristol Myers Squibb's stock surged after AbbVie's experimental schizophrenia treatment, emraclidine, failed in Phase 2 studies, boosting Bristol's new treatment, Cobenfy, which gained FDA approval in September.

Unusual activity detected; click box to confirm not a robot.

AbbVie's experimental schizophrenia treatment, emraclidine, failed to significantly improve patient outcomes in Phase 2 trials, disappointing results following the company's $9 billion acquisition of Cerevel Therapeutics.

AbbVie's phase 2 trials for schizophrenia treatment, emraclidine, missed primary endpoint, causing share decline. Despite disappointment, AbbVie continues data analysis and remains committed to psychiatric and neurological disorder treatments.

Biosimilars face barriers in the US, including the patent system, interchangeability, and PBM policies. The 'patent dance' under the BPCIA aims to expedite biosimilar market entry but is criticized for being cumbersome. Patent litigation often leads to biosimilar launch delays, as seen with adalimumab and ustekinumab biosimilars. Policy reforms, such as the Affordable Prescriptions for Patients Act, aim to address these issues but face legislative challenges.

AbbVie's Phase 2 EMPOWER trials for emraclidine in schizophrenia did not meet primary endpoint of statistically significant reduction in PANSS total score at week 6. Emraclidine was well-tolerated with a safety profile comparable to Phase 1b trial.

Roflumilast cream 0.15% showed high efficacy in treating mild to moderate atopic dermatitis in patients aged 6 years and older, with more patients achieving a validated IGA-AD score of 0/1 and minimal application site irritation.

U.S. patients gained access to lower-priced Humira biosimilars in 2023, but rebate practices by drug makers and PBMs limit competition, keeping out-of-pocket costs high. CVS Caremark and Express Scripts steer patients to preferred, not necessarily cheapest, biosimilars, preserving rebate-like strategies. Despite biosimilar market share growth, originator Humira still dominates with 82% share, contrasting with Europe's 65% five years ago.

A fixed-duration venetoclax-based regimen for first-line chronic lymphocytic leukemia (CLL) treatment results in lower long-term health care costs compared to continuous Bruton tyrosine kinase inhibitor (BTKi) treatment, with an approximate $8000 decrease in costs 6 months post-fixed-duration period. The study, based on Medicare claims data from 2016 to 2021, found similar all-cause costs during the first 12 months for both treatments but a significant drop in costs for the venetoclax-based regimen in the subsequent 6 months, largely due to the absence of prescription drug costs.